MedTrace Logo

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2017-09-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AC-150 Combo

1 drop in each eye for up to 14 days

DRUG

AC-150A 0.1%

1 drop in each eye once per day for up to 14 days

DRUG

AC-150B 0.005%

1 drop in each eye once per day for up to 14 days

DRUG

Vehicle

1 drop in each eye once per day for up to 14 days

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gail L Torkildsen, MD · Andover Eye Associates

  • Nicholas P Marsico, MD · East West Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134328 on ClinicalTrials.gov